Table of Content

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global Renal Biomarkers Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Biomarker Type
6.1 Functional Biomarker
6.1.1 Market Trends
6.1.2 Key Segments
6.1.2.1 Serum Creatinine
6.1.2.2 Serum Cystatin C
6.1.2.3 Urine Albumin
6.1.3 Market Forecast
6.2 Up-regulated Protein
6.2.1 Market Trends
6.2.2 Key Segments
6.2.2.1 Neutrophil Gelatinase-Associated Lipocalin (NGAL)
6.2.2.2 Kidney Injury Molecule-1
6.2.2.3 INTERLEUKIN-18
6.2.3 Market Forecast
6.3 Others
6.3.1 Market Trends
6.3.2 Market Forecast

7 Market Breakup by Diagnostic Technique
7.1 Enzyme-linked Immunosorbent Assay (ELISA)
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Particle-enhanced Turbidimetric Immunoassay (PETIA)
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Colorimetric Assay
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Chemiluminescent Immunoassay (CLIA)
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Liquid Chromatography Mass Spectrometry (LC-MS)
7.5.1 Market Trends
7.5.2 Market Forecast

8 Market Breakup by End User
8.1 Hospital
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Diagnostic Laboratory
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Others
8.3.1 Market Trends
8.3.2 Market Forecast

9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast

10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Abbott Laboratories
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 Beckman Coulter Inc. (Danaher Corporation)
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.3 bioM?rieux SA
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.4 BioPorto A/S
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.5 Bio-Rad Laboratories Inc.
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT Analysis
14.3.6 Enzo Biochem Inc.
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.7 F. Hoffmann-La Roche AG
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 SWOT Analysis
14.3.8 PerkinElmer Inc.
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.8.4 SWOT Analysis
14.3.9 Randox Laboratories Ltd.
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.10 Siemens AG
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.10.3 Financials
14.3.10.4 SWOT Analysis
14.3.11 Thermo Fisher Scientific Inc.
14.3.11.1 Company Overview
14.3.11.2 Product Portfolio
14.3.11.3 Financials
14.3.11.4 SWOT Analysis